AstraZeneca halts eVOLVE-Lung02 trial of volrustomig combo

Trial StartnegativevolrustomigNegative

AI Analysis

Summary

AstraZeneca has halted the eVOLVE-Lung02 trial of volrustomig combination therapy for lung cancer. The reason for the halt and clinical implications are not specified in the limited article text.

Clinical Trial Data

Outcome Details

trial halted

Importance:7/10

Sentiment:

-0.85

trial haltvolrustomiglung cancereVOLVE-Lung02

Related Companies

$AZN

Read the original article

Published by Seeking Alpha Healthcare on August 17, 2026 6:24 AM

Read Original